Trial Profile
A Phase I Study to Assess the Pharmacokinetics and Safety of Single Dose of Ravidasvir and Danoprevir/r and Repeated Doses of Ravidasvir in Combination With Danoprevir/r in Healthy Volunteers.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs Danoprevir/ritonavir (Primary) ; Ravidasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Ascletis
- 12 Jul 2021 Results from two studies NCT03430830 and NCT03288636 assessing Pharmacokinetics, safety and tolerability of ravidasvir, with and without danoprevir/ritonavir, in healthy subjects published in the Antimicrobial Agents and Chemotherapy
- 22 Sep 2017 New trial record